INTRODUCTION
============

Gastric cancer is the sixth most common malignancy and the second leading cause of cancer deaths worldwide ([@B1]). Although the 5 year-overall survival (OS) rate is 62--71% in patients treated via surgery, a significant proportion of patients develop recurrences following resection ([@B2][@B3]). Approximately 1/3 of patients (35--42%) still relapse after curative resection and adjuvant chemotherapy in Asian countries ([@B3][@B4]). Hence, identifying relevant risk factors for patients with recurrent gastric cancer is crucial for predicting prognoses and future management strategies.

After experiencing a recurrence, most patients with gastric cancer have a poor prognosis and the majority dies within 3 years ([@B4][@B5]). However, post-recurrence survival (PRS) time is variable among individual patients. Currently, most studies have dealt with prognostic factors for OS or disease-free survival (DFS) in gastric cancer; thus, many clinicopathological parameters including age, sex, histology, number of metastatic and retrieved lymph nodes (LNs), inflammatory markers, or nutritional risks beyond the tumor-node-metastasis (TNM) stage are currently available for predicting survival outcomes ([@B6][@B7][@B8][@B9]). However, few studies to date have focused on PRS in patients with recurrent gastric cancer and little is known about predictive factors that affect a patient\'s prognosis after recurrence.

Positron emission tomography/computed tomography (PET/CT) with F-18 fluorodeoxyglucose (^18^F-FDG) has been widely used for staging, evaluating treatment response, and detecting disease recurrence in gastric cancer ([@B10]). Notably, ^18^F-FDG uptake reflects the biological aggressiveness of gastric cancer; increases have been found to be an independent prognostic marker for patient outcomes in terms of OS or DFS ([@B11]). Several studies demonstrated the prognostic value of semi-quantitative ^18^F-FDG uptake of the primary tumor or metastatic LN in patients with various stages of gastric cancer ([@B12][@B13][@B14][@B15]). However, it remains uncertain whether the glycolytic activity of recurrent tumors could provide prognostic information regarding recurrent gastric cancer. Although diagnostic value of surveillance or restaging using ^18^F-FDG PET/CT has been reported by previous studies ([@B16][@B17][@B18]), there are no reports focused on metabolic activity derived from the ^18^F-FDG PET/CT restaging scan as a prognostic marker for PRS in patients with recurrent gastric cancer.

Therefore, we aimed to investigate the prognostic impact of the maximum standardized uptake value (SUV~max~) measured by ^18^F-FDG PET/CT restaging scans to predict 3-year PRS in patients with recurrent gastric cancer after curative surgical resection.

MATERIALS AND METHODS
=====================

This study followed the medical research protocols and ethical guidelines laid down by the World Medical Association\'s Declaration of Helsinki. The retrospective study protocol was approved by the Institutional Review Board (\#2018-06-028), and the need for written informed consent was waived.

Patients
--------

Study participants were selected from 1101 patients with stomach cancer who received potentially curative gastrectomy at our institution between January 2008 and December 2011. The exclusion criteria were non-curative surgery (microscopic or macroscopic residual disease \[R1-R2\] after resection), the presence of distant metastasis, the reception of any other treatment prior to surgery, a history of previous malignancy, the presence of synchronous malignancy, no recurrence during follow-up, or the absence of ^18^F-FDG PET/CT restaging scans. Finally, 47 patients with recurrent gastric cancer who underwent ^18^F-FDG PET/CT restaging scans were enrolled in this study.

All patients received total or subtotal gastrectomy along with D2 lymphadenectomy (advanced gastric cancer \[AGC\]) and D1 + β or D2 lymphadenectomy (early gastric cancer \[EGC\]). Patients had routinely been followed up every 3 months for the first year after surgery. Subsequently, patients with EGC were followed up every 6 months until 3 years while those with AGC were followed up every 6 months until 5 years. Finally, they were followed up annually using clinical and laboratory examinations with imaging and endoscopic evaluations.

Clinicopathologic and Survival Data
-----------------------------------

Clinicopathologic data, including sex, age, body weight at surgery and recurrence, percentage of weight loss, surgical and perioperative findings (e.g., type of gastrectomy, pathologic T \[pT\], pathologic N \[pN\] and TNM stages, histopathological subtypes, Lauren histotypes, ratio of the number of metastatic LNs to the total number of harvested LNs \[LNR\]), laboratory values at recurrence, and survival were reviewed and documented. The pT, pN, and TNM stages were classified according to the 8th American Joint Committee on Cancer staging system ([@B19]). Neutrophil counts, lymphocyte counts, platelet counts, and hemoglobin levels were obtained at the time of recurrence.

The date of recurrence was defined as follows: the date of imaging examination when imaging findings were used for a definitive diagnosis or the date, when an imaging modality showed abnormal findings for the first time when recurrence was histologically confirmed ([@B20]). PRS was defined as the time from the date of recurrence to the date of death; the remaining patients were censored at the last follow-up date that occurred in our institution.

^18^F-FDG PET/CT Scan and Image Analysis
----------------------------------------

All participants performed ^18^F-FDG PET/CT scans using two integrated PET/CT scanners (Discovery STE; GE Healthcare, Milwaukee, WI, USA or Biograph mCT; Siemens Healthineers Knoxville, TN, USA). Before ^18^F-FDG injection, all patients fasted for at least 6 hours and the blood glucose level of \< 150 mg/dL was maintained. Patients were encouraged to rest during the ^18^F-FDG uptake period. Images were acquired 60 minutes after 5.5 MBq/kg (Discovery STE) or 4.0 MBq/kg (Biograph mCT) of FDG was administered intravenously. A low-dose CT scan (Discovery STE; peak voltage of 120 kVp and slice thickness of 3.75 mm, Biograph mCT; peak voltage of 120 kVp and slice thickness of 3 mm) was acquired, and PET scan was obtained with an acquisition time of 3 min/bed position with the Discovery STE and 1.5 min/bed position with the Biograph mCT in 3-dimensional mode. Images were reconstructed via ordered-subset expectation maximum iterative reconstruction with attenuation correction.

The images were retrospectively interpreted on an Advantage Workstation 4.3 (GE Healthcare) by two board-certified nuclear medicine physicians. Both readers had knowledge of all available imaging studies; however, they were blinded to the patients\' survival data. For the semiquantitative analysis, SUV~max~ was measured by manually placing circular regions of interest over the visually discernable ^18^F-FDG avid metastatic lesions on the attenuation-corrected transaxial ^18^F-FDG PET images. To evaluate patients with anastomotic recurrence, abnormally increased uptake at the anastomosis site corresponding to endoscopic and histopathological findings was considered as a recurring malignant lesion. The SUV~max~ was calculated using the following formula: SUV~max~ = maximum activity in the region of interest (MBq/g)/ (injected dose \[MBq\]/body weight \[g\]).

Statistical Analyses
--------------------

Numeric data are expressed as medians and interquartile ranges (IQRs), while categorical variables are reported as numbers and percentages. The optimal cutoff values for continuous variables for 3-year PRS predictions were derived from maximally selected chi-square statistics using R package 'Maxstat' ([@B21]). Recurrence timing was divided into early (≤ 2 years from the surgery date) and late (\> 2 years from the surgery date) ([@B22]). The Kaplan-Meier method was used to estimate the 3-year PRS rate. All *p* values \< 0.05 were considered statistically significant. For investigating predictive parameters affecting 3-year PRS, multivariate Cox proportional-hazards regression models were performed with the stepwise approach. Variables with *p* value \< 0.05 in the univariate analysis were selected for multivariate analysis; the hazards ratio (HR) and 95% confidence interval (CI) were estimated for each parameter. Statistical analyses were performed using MedCalc for Windows, version 18.10.2 (MedCalc Software, Ostend, Belgium) and R version 3.4.3 software (<http://www.r-project.org>, R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
=======

Patient Characteristics
-----------------------

In total, 47 patients with recurrent gastric cancer who received curative surgical resection were retrospectively analyzed. Recurrence was confirmed histologically in 33 (70.2%) of the 47 patients, and clinically diagnosed in the remaining 14 patients (29.8%). Overall, 39 of the 47 patients (83.0%) were confirmed dead within 3 years after recurrence during the median follow-up period of 30.3 months (IQR, 18.1--62.6 months), and 3-year PRS rates were 17.0%.

The median PRS time was 10.0 months (IQR, 4.7--19.8 months) in all patients, 50.7 months (IQR, 40.3--71.8 months) in patients who survived over 3 years while 7.7 months (IQR, 4.5--12.4 months) in those who died within 3 years. The median SUV~max~ obtained from restaging ^18^F-FDG PET/CT scans were 4.0 (IQR, 3.3--4.7) in patients surviving over 3 years and 7.3 (IQR, 5.0--9.9) in those who died within 3 years.

The characteristics of the enrolled patients (median age, 59.0 years; IQR, 46.0--64.5 years) are listed in [Table 1](#T1){ref-type="table"}. Most patients were diagnosed with AGC (89.4%) while only five patients had EGC (10.6%). Pathologic TNM stage III was most frequently observed (63.9%). According to the World Health Organization classification, 31 patients (66.0%) were categorized as having adenocarcinoma (30 tubular and 1 mucinous types) and 16 (34.0%) had a signet ring cell type. In terms of the Lauren histotype, 33 patients (70.2%) were diffuse and 14 (29.8%) were intestinal.

The median time to recurrence (i.e., DFS) was 17.8 months (IQR, 12.4--35.9 months), and a significant portion of patients (63.9%) recurred within 2 years. Six of the 47 patients (12.8%) experienced locoregional recurrence, 31 (65.9%) had distant metastasis, and 10 (21.3%) developed both locoregional and distant failure at the time of recurrence. Most frequent patterns of distant metastasis were hematogenous (60.0%), followed by peritoneal recurrence (18.3%), and then lymphatic metastasis (16.7%). The therapeutic aim of recurrent disease was as follows: 12 patients (25.5%) underwent potentially curative treatment, 27 patients (57.5%) underwent palliative treatment, and the remaining eight patients (17.0%) received only supportive care.

Uni- and Multivariate Analyses
------------------------------

The optimal cutoff values of patients\' age, LNR, SUV~max~, weight loss percentage, and hemoglobin level as well as for the neutrophil, lymphocyte and platelet counts for a 3-year PRS were 50, 0.063, 5.1, 14.7, 11.4, 2997, 1084, and 154000, respectively. SUV~max~ performed a Kaplan--Meier analysis with a log-rank test to compare 3-year PRS stratification. Notably, high SUV~max~ was associated with a significantly lower 3-year PRS rate compared to low SUV~max~ (3.5% vs. 38.9%, *p* \< 0.001) ([Fig. 1](#F1){ref-type="fig"}).

Values above and below the optimal cutoff for LNR, SUV~max~, weight loss, neutrophil count, and recurrence timing were significantly associated with 3-year PRS in the univariate Cox proportional-hazards regression analysis ([Table 2](#T2){ref-type="table"}). In the multivariate analysis, SUV~max~ (HR, 2.57; 95% CI, 1.16--5.69; *p* = 0.012), weight loss (HR, 2.24; 95% CI, 1.11--4.56; *p* = 0.025), and neutrophil count (HR, 2.68; 95% CI, 1.32--5.43; *p* = 0.006) were independently prognostic for 3-year PRS. However, the LNR and recurrence timing were no longer statistically significant in the multivariate analysis. A visual presentation of independent prognostic factors for each study participant is displayed in [Figure 2](#F2){ref-type="fig"}.

DISCUSSION
==========

In the current study, we assessed the prognostic value of SUV~max~ on ^18^F-FDG PET/CT in patients with recurrent gastric cancer after curative surgical resection. Several studies have reported the prognostic factors for PRS in a variety of malignancies, including stomach, breast, hepatocellular, cervical, and non-small-cell lung cancers ([@B23][@B24][@B25][@B26]). However, to the best of our knowledge, no studies have established the prognostic value of ^18^F-FDG PET/CT after recurrence in the field of gastric cancer. Our results demonstrated that the SUV~max~ was an independent survival predictor for 3-year PRS in the multivariate analysis.

Death after recurrence usually occurs rapidly even after achieving curative intent resection. Despite more than 80% of patients dying within 3 years following a recurrence ([@B4][@B5]), there were some long-term survivors. In our study, 17% of the patients lived more than 3 years after relapse and their median PRS was over 50 months. In that regard, predicting patient outcomes after recurrence might be helpful for creating a personalized therapeutic approach or in follow-up planning. Hence, our results suggest a potential value of SUV~max~ for further prognostication in patients with recurrent gastric cancer. The SUV~max~, a simple measurement and the most widely used metabolic parameter obtained by ^18^F-FDG PET/CT ([@B27]), consistently estimated 3-year PRS outcomes. This may be because increased ^18^F-FDG uptake reflects biological aggressiveness not only the initial staging of gastric cancer but also in cases of recurrence ([@B13][@B28]). Thus, ^18^F-FDG PET/CT seems to play an additional prognostication role in patients with recurrent disease regarding their survival and in detecting recurrence.

Inflammatory response to cancer contributes to carcinogenesis and tumor progression. Therefore, inflammatory biomarkers have recently been evaluated as valuable prognostic factors in various type of cancers ([@B29]); moreover, the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been widely evaluated for prognostication in gastric cancers ([@B30]). Some studies reported NLR to be more predictive for prognoses than PLR ([@B31][@B32]). More recently, Guner et al. ([@B9]) demonstrated that simple parameters (e.g., neutrophil count) are better for predicting short- and long-term outcomes in patients with surgically resected gastric cancers compared to complex parameters (e.g., NLR). Our findings show that high neutrophil counts upon recurrence were associated with poor prognoses in patients with relapsed gastric cancer.

The percentage of weight loss, as a simple nutritional parameter, was also an independent survival predictor for PRS in the present study. Weight loss can be an indicator of malnutrition and is closely associated with patients\' postoperative quality of life ([@B33]). Aoyama et al. ([@B34]) found that postoperative weight loss ≥ 15% could lead to worse survival outcomes through a significantly decreased compliance of adjuvant treatments. As appropriate nutritional care could improve survival after recurrence and significantly reduce patients\' perioperative morbidity and mortality ([@B35]), further studies applying appropriate nutritional assessment tools might help validate whether the patient\'s nutritional status could affect PRS or not.

Increased glucose consumption and glycolysis are critical hallmarks of gastric cancer; therapeutically targeting tumor cell metabolism processes, such as glucose metabolism, is more convenient approach and is associated with fewer side effects than targeting other biologic systems since cellular metabolic pathways represent the terminus of biologic systems and control the other systems genetically ([@B36][@B37]). Thus, anti-tumor therapies targeting this aspect of cancer are new and appear promising. There have been several studies on therapies reducing glucose consumption of gastric cancer cells ([@B38]), suppressing hexokinase II ([@B39][@B40]), or blocking the Warburg effect in combination with other therapies ([@B41]) in *in vitro* and preclinical *in vivo* settings. As glycolysis-targeted or other novel anti-tumor therapies are discovered, the application of ^18^F-FDG PET/CT, a clinical imaging surrogate for enhanced glucose metabolism, could be a considerable strategy to evaluate therapeutic responses and prognostication in recurrent gastric cancer.

The present study had some limitations. The retrospective nature and the relatively small patient dataset from a single institution were the main limitations; these might also have subjected the study to selection bias. Moreover, patients with recurrent cancer who did not undergo ^18^F-FDG PET/CT scans were not included. However, our study suggests the potential value of ^18^F-FDG uptake for further prognostication in patients with recurrent gastric cancer. In addition, two different PET/CT scanners (Discovery STE and Biograph mCT) were used. The difference in the resolution and administered ^18^F-FDG doses could have affected SUV~max~ values. However, a prior study has validated that the difference in the SUV~max~ values of the same lesion between two different scanners is \< 0.05 ([@B42]). Despite these limitations, we suggest that ^18^F-FDG uptake at recurrence might be helpful in predicting survival outcomes in patients with recurrent gastric cancer. Further large-scale prospective studies should be conducted using ^18^F-FDG PET/CT to assess the prognostic value in recurrent gastric cancer.

In conclusion, the present study revealed that SUV~max~ could estimate survival outcomes in patients with recurrent gastric cancer after curative resection. Thus, restaging ^18^F-FDG PET/CT scans could be used to estimate life expectancy after recurrence and may bolster the role of ^18^F-FDG PET/CT in oncology practice.
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![Cumulative PRS curves of 47 patients with recurrent gastric cancer stratified by SUV~max~.\
High SUV~max~ was associated with significantly lower 3-year PRS rate compared to low SUV~max~ (3.5% vs. 38.9%, *p* \< 0.001). PRS = post-recurrence survival, SUV~max~ = maximum standardized uptake value](kjr-21-829-g001){#F1}

![Visual summary of independent prognostic factors in series of 47 patients.\
Red color indicates patients who died within 3 years after recurrence, and blue color indicates those who survived. Overall survival time after recurrence and numeric data of each parameter are depicted on 4-color scale.](kjr-21-829-g002){#F2}

###### Patient Characteristics Depending on 3-Year Post-Recurrence Survival Status

![](kjr-21-829-i001)

  Variables                           Total (n = 47) n (%) or Median (IQR)   Live More than 3 Years after Recurrence (n = 8) n (%) or Median (IQR)   Death within 3 Years after Recurrence (n = 39) n (%) or Median (IQR)   *P*
  ----------------------------------- -------------------------------------- ----------------------------------------------------------------------- ---------------------------------------------------------------------- -------
  Age at diagnosis, years             59.0 (46.0--64.5)                      55.5 (47.5--65.5)                                                       59.0 (46.0--64.0)                                                      0.723
  Sex                                                                                                                                                                                                                       0.146
   Male                               31 (66.0)                              3 (37.5)                                                                28 (71.8)                                                              
   Female                             16 (34.0)                              5 (62.5)                                                                11 (28.2)                                                              
  Type of gastrectomy                                                                                                                                                                                                       0.536
   Total                              13 (27.7)                              1 (12.5)                                                                12 (30.8)                                                              
   Subtotal                           34 (72.3)                              7 (87.5)                                                                27 (69.2)                                                              
  Pathologic T stage^\*^                                                                                                                                                                                                    0.328
   T1                                 5 (10.6)                               2 (25.0)                                                                3 (7.7)                                                                
   T2                                 6 (12.8)                               1 (12.5)                                                                5 (12.8)                                                               
   T3                                 7 (14.9)                               2 (25.0)                                                                5 (12.8)                                                               
   T4                                 29 (61.7)                              3 (37.5)                                                                26 (66.7)                                                              
  Pathologic N stage^\*^                                                                                                                                                                                                    0.203
   N0                                 12 (25.5)                              4 (50.0)                                                                8 (20.5)                                                               
   N1                                 3 (6.4)                                1 (12.5)                                                                2 (5.1)                                                                
   N2                                 6 (12.8)                               0 (0.0)                                                                 6 (15.4)                                                               
   N3                                 26 (55.3)                              3 (37.5)                                                                23 (59.0)                                                              
  TNM stage\*                                                                                                                                                                                                               0.178
   I                                  5 (10.6)                               2 (25.0)                                                                3 (7.7)                                                                
   II                                 12 (25.5)                              3 (37.5)                                                                9 (23.1)                                                               
   III                                30 (63.9)                              3 (37.5)                                                                27 (69.2)                                                              
  Histopathologic subtype                                                                                                                                                                                                   0.759
   Adenocarcinoma                     31 (66.0)                              6 (75.0)                                                                25 (64.1)                                                              
   Signet ring cell                   16 (34.0)                              2 (25.0)                                                                14 (35.9)                                                              
  Lauren histotype                                                                                                                                                                                                          0.343
   Diffuse                            33 (70.2)                              4 (50.0)                                                                29 (74.4)                                                              
   Intestinal                         14 (29.8)                              4 (50.0)                                                                10 (25.6)                                                              
  LNR                                 0.11 (0.01--0.33)                      0.01 (0.00--0.33)                                                       0.11 (0.05--0.33)                                                      0.311
  SUV~max~                            6.3 (4.2--9.2)                         4.0 (3.3--4.7)                                                          7.3 (5.0--9.9)                                                         0.015
  Weight loss, %                      11.6 (8.6--15.8)                       10.3 (5.0--13.9)                                                        11.6 (9.8--17.5)                                                       0.130
  Hemoglobin, g/dL                    11.7 (11.1--12.6)                      11.8 (11.6--12.1)                                                       11.7 (10.9--12.6)                                                      0.671
  Neutrophil count, cells/uL          3503 (2601--4894)                      2742 (2298--3497)                                                       3934 (2691--5338)                                                      0.125
  Lymphocyte count, cells/uL          1317 (964--1739)                       1235 (869--1875)                                                        1335 (964--1739)                                                       0.588
  Platelet count, x10^3^cells/uL      228 (193--275)                         221 (191--268)                                                          231 (193--278)                                                         0.887
  Recurrence timing                                                                                                                                                                                                         0.035
   Early, ≤ 2 years                   30 (63.9)                              2 (25.0)                                                                28 (71.8)                                                              
   Late, \> 2 years                   17 (36.1)                              6 (75.0)                                                                11 (28.2)                                                              
  First sites of recurrence                                                                                                                                                                                                 0.192
   Locoregional recurrence only       6 (12.8)                               2 (25.0)                                                                4 (10.3)                                                               
   Distant metastasis only            31 (65.9)                              6 (75.0)                                                                25 (64.1)                                                              
   Locoregional and distant failure   10 (21.3)                              0 (0.0)                                                                 10 (25.6)                                                              

^\*^According to 8th AJCC staging system. AJCC = American Joint Committee on Cancer, IQR = interquartile range, LNR = ratio of number of metastatic lymph nodes to total number of harvested lymph nodes, SUV~max~ = maximum standardized uptake value, TNM = tumor-node-metastasis

###### Univariate and Multivariate Analyses for 3-Year Post-Recurrence Survival
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  Variables                           Univariate Analysis   Multivariate Analysis                       
  ----------------------------------- --------------------- ----------------------- ------------------- -------
  Age at diagnosis, years                                                                               
   \< 50^\*^                                                                                            
   ≥ 50                               1.57 (0.80--3.06)     0.187                                       
  Sex                                                                                                   
   Male^\*^                                                                                             
   Female                             0.54 (0.27--1.09)     0.086                                       
  Type of gastrectomy                                                                                   
   Total^\*^                                                                                            
   Subtotal                           0.69 (0.35--1.36)     0.282                                       
  Pathologic T stage^†^                                                                                 
   T1^\*^                                                                                               
   T2                                 1.35 (0.32--5.71)     0.682                                       
   T3                                 0.86 (0.21--3.61)     0.837                                       
   T4                                 1.77 (0.53--5.89)     0.355                                       
  Pathologic N stage^†^                                                                                 
   N0^\*^                                                                                               
   N1                                 0.78 (0.17--3.69)     0.754                                       
   N2                                 2.39 (0.79--7.13)     0.119                                       
   N3                                 2.01 (0.89--4.51)     0.091                                       
  TNM stage^†^                                                                                          
   I^\*^                                                                                                
   II                                 0.95 (0.26--3.53)     0.942                                       
   III                                1.79 (0.54--5.97)     0.337                                       
  Histopathologic subtype                                                                               
   Adenocarcinoma^\*^                                                                                   
   Signet ring cell                   1.26 (0.65--2.43)     0.493                                       
  Lauren histotype                                                                                      
   Diffuse^\*^                                                                                          
   Intestinal                         0.68 (0.33--1.41)     0.298                                       
  LNR                                                                                                   
   ≤ 0.063^\*^                                                                                          
   \> 0.063                           2.22 (1.12--4.43)     0.023                                       
  SUVmax                                                                                                
   ≤ 5.1^\*^                                                                                            
   \> 5.1                             3.30 (1.58--6.87)     0.001                   2.57 (1.16--5.69)   0.012
  Weight loss, %                                                                                        
   ≤ 14.7^\*^                                                                                           
   \> 14.7                            2.91 (1.48--5.71)     0.002                   2.24 (1.11--4.56)   0.025
  Hemoglobin, g/dL                                                                                      
   ≥ 11.4^\*^                                                                                           
   \< 11.4                            1.88 (0.98--3.58)     0.055                                       
  Neutrophil count, cells/uL                                                                            
   ≤ 2997^\*^                                                                                           
   \> 2997                            2.89 (1.45--5.79)     0.003                   2.68 (1.32--5.43)   0.006
  Lymphocyte count, cells/uL                                                                            
   ≤ 1084^\*^                                                                                           
   \> 1084                            0.58 (0.30--1.10)     0.095                                       
  Platelet count, cells/uL                                                                              
   ≥ 154000^\*^                                                                                         
   \< 154000                          2.16 (0.88--5.31)     0.094                                       
  Recurrence timing                                                                                     
   Early, ≤ 2 years                   2.40 (1.18--4.91)     0.016                                       
   Late, \> 2 years^\*^                                                                                 
  First sites of recurrence                                                                             
   Locoregional recurrence only^\*^                                                                     
   Distant metastasis only            1.49 (0.52--4.31)     0.458                                       
   Locoregional and distant failure   2.62 (0.81--8.41)     0.107                                       

^\*^Reference of categorical parameter, ^†^According to 8th AJCC staging system. CI = confidence interval, HR = hazard ratio
